Tune into our webinars for subject matter expertise on a variety of key topics.
Webinars
Upcoming Webinars:
Sorry, no upcoming webinars. Check later for updates.
Previous / On-Demand Webinars:
PCWG3 (Prostate Cancer Working Group 3) and Oncology Imaging Endpoints
Jan 18, 2023 | 11 AM EST
Duration: 45 Minutes
Prostate cancer is one of the most common cancer types in men. With bone as a frequent metastatic site, response assessments for prostate cancer have additional considerations beyond RECIST 1.1.
Fundamentals of iRECIST and Imaging Endpoints
Nov 16, 2022 | 11 AM EST
Duration: 45 Minutes
iRECIST provides guidance for solid tumor response criteria in immunotherapy to accommodate possible pseudoprogression, which may occur in some subjects. In this presentation, MERIT will discuss the rules and principles of iRECIST, imaging endpoints, and special considerations for using iRECIST response criteria.
Take Control of Your Clinical Trial:
How an Imaging Core Lab Can Help Overcome Common Study Challenges
How an Imaging Core Lab Can Help Overcome Common Study Challenges
Oct 12, 2022 | 11 AM EST
Duration: 45 Minutes
Does your oncology clinical trial have an imaging component? Are you new to working with imaging core labs? An imaging core lab can provide your team with resources, knowledge, and experience that can help make your study a success.
RANO and Oncology Trial Endpoints
Sep 14, 2022 | 11 AM EST
Duration: 45 Minutes
The Response Assessment in Neuro-Oncology (RANO) group provides various central nervous system-related tumor response criteria and guidance for assessments. In this webinar, MERIT will discuss the principles and recommendations of RANO response criteria for high grade glioma (HGG) and the imaging endpoint information that needs to be collected for clinical trials.
RECIST 1.1 and Oncology Trial Endpoints
Aug 11, 2022 | 11 AM EST
Duration: 45 Minutes
RECIST 1.1 is the standard response criteria for solid tumors and has been a basis for adaptation and variation of other response criteria such as mRECIST, irRECIST, iRECIST, and so on. In this on-demand webinar recording, MERIT discusses the principles of RECIST 1.1, the information needed to collect imaging endpoints, and special considerations while using the RECIST 1.1 criteria.
WHY MERIT?
Transparent communication with prompt access to in-house experts
Deep bench of experienced and tenured staff trained in industry sponsored clinical trials, with a dedicated team for every project
We are often able to provide competitive pricing and shortened timelines for our sponsors and partners through efficiences gained from decades of experience
Proven track record supporting FDA approval of numerous products
EXCELSIORTM, our cloud-based software solution, is designed for imaging studies and is FDA 510(K) cleared for ophthalmic indications as well as HIPAA, 21 CFR Part11, and GDPR compliant. EXCELSIOR enhances the efficiency and accuracy of your imaging data collection and interpretation
MERIT’s innovative respiratory software application, CompleClinical®, simplifies and streamlines the pulmonary clinical trial process, improving the efficiency and accuracy of data capture, management, and grading of spirometry data
Personalized attention, scalable solutions, and reliable clinical trial endpoint services
Some companies tend to overpromise and underdeliver, which puts your study success at risk. If you’re looking for a clinical trial endpoint services provider that will value your partnership and make your study a priority, consider MERIT.
